HAIFA, Israel, January 19 /PRNewswire/ -- InSightec Ltd. announced today
that its non-invasive MR guided focused ultrasound (MRgFUS) technology, will
be featured in four presentations at the New European Surgical Academy's NESA
Days 2006, an interdisciplinary endoscopy conference focused on optimizing,
simplifying and standardizing surgical procedures. The meeting takes place
January 19 to 21, 2006 at the Hilton Hotel in Berlin, Germany and the
presentations will highlight the global use of MRgFUS as a new, non-invasive
surgical treatment for a variety of benign and cancerous tumors.
MRgFUS combines Magnetic Resonance Imaging (MRI) to visualize tissue in
the body, plan and monitor the treatment and outcome in real time and high
intensity focused ultrasound energy to thermally ablate (destroy) tissue. MR
thermal feedback, provided uniquely by the system, allows the physician to
control and adjust the treatment to ensure that the targeted tumor is fully
treated and other tissue is avoided.
ExAblate 2000 is the only MRgFUS system approved by the FDA (U.S. Food
and Drug Administration) as a non-invasive, outpatient procedure to treat
uterine fibroids. The device also has the European CE mark and ISO 9001.Over
1500 women have been treated worldwide for symptomatic uterine fibroids.
The company has begun clinical trials to study the technology's use in
other indications including breast, bone, liver and brain tumors. Currently,
clinical trials are being conducted for metastatic bone and liver tumors at
Charite Hospital in Berlin and St. Mary's Hospital in London.
Following are ExAblate talks at NESA Days 2006:
Presentation Title Presenter
The Use of FUS on Malignancies Moshe Zvi Papa, MD
Focused Ultrasound Therapy: Elizabeth A. Stewart, MD
Uterine Fibroids and Beyond
Preliminary Experience with Alexander Beck, MD
Treatment of Bone and Liver
tumors with MR guided Focused
Round Table: From Surgery to Zion Ben Rafael, MD, Moshe Zvi
Minimal Invasive and Papa , MD, Gralf Popken, MD,
Non-invasive Procedures Elizabeth A. Stewart, MD,
Gerhard Buess, MD, Michael
Stark, MD, Dov Maor, PhD.
About Uterine Fibroids
Uterine fibroids are benign growths in the uterus that affect
approximately 13 million women of child bearing age in the U.S. Each year
approximately 200,000 women have hysterectomies to treat uterine fibroids.
Unlike hysterectomy, myomectomy and UAE, this technology is completely
non-invasive using MRgFUS to thermally ablate (destroy) tumors in the uterus.
For women this means no hospital stay and only 2-3 days of recovery as
opposed to the one week (UAE); two weeks (myomectomy); or six weeks
(hysterectomy) usually associated with treatment of this condition.
ExAblate has been recognized for its innovation and potential to serve
mankind and has been awarded the 2004 EU's Information Society Technologies
grand prize, the The Wall Street Journal's 2004 Technology Innovation Awards,
and Advanced Imaging's 2005 Solutions of the Year.
InSightec Ltd. is a privately held company owned by Elbit Medical Imaging
(EMI), General Electric, private investors and employees. It was founded in
1999 to develop the breakthrough MR guided Focused Ultrasound technology and
transform it into the next generation operating room. Headquartered near
Haifa, Israel, the company has over 120 employees and has invested more than
$100 million in research, development, and clinical investigations. Its U.S.
headquarters are located in Dallas, Texas. For more information, please go
NESA was founded in 2004, and includes members, departments, and
hospitals in 27 countries. NESA deals among others with re-evaluation of
surgical procedures in order to optimize, simplify and standardize them.
NESA's five disciplines are: general surgery, obstetrics and gynecology,
urology, otolaryngology, and anaesthesiology. In NESA DAYS 2006 experts with
high international reputation will present a wide variety of re-evaluated and
optimized surgical endoscopic procedures next to new developments in basic
For media inquiries, contact:
Lazar Partners, Ltd.
For more information about uterine fibroids, please visit
SOURCE InSightec Ltd.